## CDNA: CareDx, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 9.8% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($18.80)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Nikko Asset Management Americas Inc. Reduces Position in CareDx, Inc. $CDNA**
- Source: MarketBeat | 20251214T110908 | Neutral | Relevance: 100%
- Nikko Asset Management Americas Inc. reduced its stake in CareDx, Inc. by 10.3% in the second quarter, selling over 141,000 shares but still retaining a significant holding valued at $24.14 million. Despite this, CareDx reported strong Q2 earnings, beating analyst expectations with an EPS of $0.28 and revenue of $100.06 million, reflecting a 20.7% year-over-year growth. The company currently holds an average "Hold" rating from analysts, with a target price of $26.00.

**2. CareDx, Inc. $CDNA Shares Sold by Bellevue Group AG**
- Source: MarketBeat | 20251213T090917 | Somewhat-Bullish | Relevance: 100%
- Bellevue Group AG reduced its stake in CareDx, Inc. (NASDAQ:CDNA) by 15.4% in the second quarter, selling over 136,000 shares. Despite this, CareDx reported strong quarterly earnings, beating analyst expectations with $0.28 EPS and $100.06 million in revenue, leading to a "Hold" consensus rating among analysts with an average target price of $26.00. The stock currently trades around $20.56 with a market capitalization of $1.06 billion.

**3. CareDx Reforms Get Nod Following $20 Million Investor Class Deal**
- Source: Bloomberg Law News | 20251210T182400 | Neutral | Relevance: 100%
- A federal judge has preliminarily approved an agreement for CareDx Inc. to implement internal reforms after a $20 million class settlement with investors. These reforms, including new committee activities, training, and external review, aim to address allegations of illegal revenue-boosting schemes. The reforms will be in place for four years, following a prior approval of the investor settlement.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 4 ($0.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 1 |

**Top Holders:**
- Blackrock Inc.: 9.3% (+2.3%)
- Vanguard Group Inc: 7.3% (-23.6%)
- BAMCO Inc.: 6.1% (+29.5%)
- State Street Corpora: 5.0% (+17.7%)
- Ophir Asset Manageme: 4.3% (+16.1%)

### Key Risks

1. High beta (2.54) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.1%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +6.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 23.5x attractive for 27% earnings growth. Quality metrics strong (ROE 24%, margin 20%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.39). Institutional flow bullish (9 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.1B |
| Beta | 2.54 |
| 52W Range | $10.96 - $25.95 |
| Short Interest | 13.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.12 |
| Forward P/E | 23.5 |
| Current P/E | 29.9 |
| YoY Growth | 26.9% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 3.0% to 9.8% (+6.9% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (9.8% > 6.0%), caution on chasing. MRS_5 at 6.2% confirms short-term momentum alignment. Outperforming sector by 10.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 72, risk of mean reversion. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 9.84% (CS: 98) | Strong |
| RSI_14 | 72.0 | Overbought |
| MACD Histogram | 0.19 | Bullish |
| vs SMA20 | 1.151x | Above |
| vs SMA50 | 1.271x | Above |
| vs SMA200 | 1.257x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $20.56
- **Stop Loss:** $18.80 (8.6% risk)
- **Target:** $22.32 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 568
- **Position Value:** $11,678.08
- **Portfolio %:** 11.68%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-03-02 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.14 | $0.28 | +97.6% |
| 2025Q2 | $0.12 | $0.10 | -18.0% |
| 2025Q1 | $0.07 | $0.10 | +46.4% |
| 2024Q4 | $0.15 | $0.18 | +22.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*